|
Catalogue
Number
|
Product
|
Order number / Unit
|
|
|
800
|
Cryptand 222
|
800.0015: 15 mg per vial
800.0020: 20 mg per vial
800.0025: 25 mg per vial
800.0100: 100 mg per vial
800.0250: 250 mg per vial
800.1000: 1 g per vial
Please inquire for customized
filling and bulk quantities.
|
|
|
Aminopolyether used to dissolve K+ salts in nucleophilic [18F]labelling reactions
|
|
|
|
|
|
|
|
|
Molar Mass: 376.49
|
|
|
C18H36N2O6
|
|
|
[23978-09-8]
|
|
|
|
|
|
Colourless crystals packaged in dark glass crimp cap vials (8000.0015 and 8000.0020) or screw cap vials (8000.0100, 8000.0250, and 8000.1000).
|
|
|
|
|
|
|
|
|
Purity: > 99 %
|
|
|
Certificates:
CoA; 1H NMR and IR spectra, GC-MS
|
|
|
Chemical Name:
CA index name: 4,7,13,16,21,24-Hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane
|
|
|
Synonymes:
2,2,2-Crypt; 2,2,2-Cryptand; 2,2,2-Cryptate; Crypt-2,2,2; Cryptand 2.2.2; Cryptand C 222; Cryptate 222; Cryptating agent 222; Cryptofix 222; Kryptand 222; Kryptofix 222;
|
|
|
Literature:
1. Huang J.C. Comparison of Various Requirements of the Quality Assurance Procedures for 18F-FDG Injection. J. Nucl. Med. 2002, 43, 1495-1506.
|
|
|
2. Lemaire C. et al. No-carrier-added regioselective preparation of 6-[18F]fluoro-L-DOPA. J. Nucl. Med. 1990, 31, 1247-51.
|
|
|
3. Moerlein S. et al. Elimination of contaminant Kryptofix 2.2.2 in the routine production of 2-[18F]fluoro-2-deoxy-D-glucose. Int. J. Rad. Appl. Instrum. [A] 1989, 40, 741-3.
|
|
|
4. Chaly T. et al. Thin layer chromatographic detection of Kryptofix 222 in the routine synthesis of [18F]2-fluoro-2-deoxy-D-glucose. Int. J. Rad. Appl. Instrum. [B] 1989, 16, 385-7.
|
|
|
|
|
|
date of product catalogue issue:
22 December 2011
|